A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Systemic Lupus Erythematosus Patients With Active Lupus Arthritis.

Trial Profile

A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Systemic Lupus Erythematosus Patients With Active Lupus Arthritis.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2016

At a glance

  • Drugs Laquinimod (Primary)
  • Indications Arthritis; Systemic lupus erythematosus
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Oct 2012 Planned End Date changed from 1 Aug 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
    • 31 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top